EVFM
Evofem Biosciences, Inc.Company Information
- Company Name
- Evofem Biosciences, Inc.
- CIK
- CIK0001618835
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- EVFM: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- EVFM
SEC filing data through
Insider Sentiment
- Last purchase
- 2022-05-27
- Last sale
- 2024-01-12
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 114
Institutional Sentiment
- As of
- 2022-09-30
- Institutional shares owned
- 841
- Shares outstanding
- 659,480
- Ownership
- 0.13%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 0.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Restricted Cash Current | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Cash And Cash Equivalents At Carrying Value | - | 1 | 1 | - | - | 0 | 1 | - | - | - | - | - | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | 0 | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 2 | 1 | 12 | 4 | 5 | 1 | 10 | 5 | 5 | 4 | 6 | 6 | ||||||
| Inventory Net | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Assets Current | 6 | 6 | 15 | 8 | 9 | 6 | 14 | 9 | 7 | 7 | 9 | 12 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finite Lived Intangible Assets Net | 1 | 1 | 4 | 5 | 5 | 6 | 10 | 14 | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 8 | 7 | 20 | 14 | 14 | 13 | 24 | 24 | 9 | 8 | 11 | 13 | ||||||
Liabilities Current | ||||||||||||||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 15 | 13 | ||||||
| Accounts Payable Current | 12 | 12 | 13 | 12 | 12 | 11 | 16 | 17 | 16 | 16 | 17 | 16 | ||||||
| Short Term Borrowings | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 | - | - | - | ||||||
| Accrued Liabilities Current | 2 | 1 | 1 | 1 | 3 | 3 | 6 | 5 | 5 | 5 | 4 | 5 | ||||||
| Employee Related Liabilities Current | 2 | 1 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Current | 7 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 4 | 2 | - | ||||||
| Other Liabilities Current | 11 | 10 | 12 | 8 | 8 | 7 | 7 | - | 4 | 3 | 3 | 4 | ||||||
| Liabilities Current | 89 | 79 | 85 | 78 | 74 | 71 | 80 | 76 | 73 | 74 | 72 | 68 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 90 | 80 | 90 | 84 | 79 | 78 | 90 | 90 | 73 | 74 | 72 | 68 | ||||||
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | ||||||||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 2 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Additional Paid In Capital | 832 | 832 | 832 | 832 | 831 | 829 | 829 | 825 | 824 | 823 | 823 | 829 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -5 | -7 | -9 | -7 | -3 | -2 | -3 | -2 | -1 | -1 | -1 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -914 | -903 | -897 | -900 | -898 | -897 | -898 | -895 | -892 | -894 | -889 | -885 | ||||||
| Stockholders Equity | -88 | -78 | -74 | -75 | -70 | -70 | -71 | -71 | -69 | -71 | -67 | -56 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 8 | 7 | 20 | 14 | 14 | 13 | 24 | 24 | 9 | 8 | 11 | 13 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Temporary Equity Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | ||||||
| Common Stock Shares Issued | 133 | 133 | 127 | 124 | 119 | 113 | 113 | 100 | 83 | 49 | 20 | 6 | ||||||
| Shares Outstanding | 133 | 133 | 127 | 124 | 119 | 113 | 113 | 100 | 83 | 49 | 20 | 6 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEvofem Biosciences, Inc. (EVFM) — SEC Financial Statements & Analysis
Evofem Biosciences, Inc. (EVFM) is a pharmaceutical preparations company, incorporated in DE. Evofem Biosciences, Inc. trades on OTC as: EVFM. Evofem Biosciences, Inc. (EVFM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Evofem Biosciences, Inc. carries a market cap of $1.10M, a P/E ratio of -0.07x, a P/B ratio of -0.01x, a P/S ratio of 0.06x, an enterprise value of $1.18M, and an EV/EBITDA multiple of -0.43x. On profitability, it posts a gross margin of 75.52%, an operating margin of -15.31%, a net margin of -85.45%, a Return on Equity (ROE) of 19.63%, and a Return on Assets (ROA) of -140.79%. Per share, it reports EPS of $-0.11, diluted EPS of $-0.11, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 4.49% year-over-year, net income growth of 145.21% year-over-year, and EPS growth of 115.14% year-over-year. On the balance sheet, it maintains a current ratio of 0.07x, a quick ratio of 0.03x, working capital of $-82.53M, a debt-to-equity ratio of -1.03x, a debt ratio of 11.97, an interest coverage ratio of -1.13x, free cash flow of $-477.00K (TTM), and net debt of $77.00K. Figures sourced from SEC EDGAR.
- Market Cap
- $1.10M
- P/E TTM
- -0.07x
- EPS TTM
- $-0.11
- P/B TTM
- -0.01x
- ROE TTM
- 19.63%
- ROA TTM
- -140.79%
- Debt To Equity
- -1.03x
- Free Cash Flow TTM
- $-477.00K
- Net Revenue TTM Growth 1Y
- 4.49%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Evofem Biosciences, Inc. in?
Evofem Biosciences, Inc. (EVFM) operates in the Pharmaceutical Preparations industry.
What exchange does EVFM trade on?
Evofem Biosciences, Inc. (EVFM) trades on the OTC.
Where is Evofem Biosciences, Inc. incorporated?
Evofem Biosciences, Inc. is incorporated in DE.
When was Evofem Biosciences, Inc. (EVFM)'s most recent SEC filing?
Evofem Biosciences, Inc. (EVFM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is EVFM's market cap?
Evofem Biosciences, Inc. (EVFM) has a market capitalization of $1.10M as of 2026-06-30.
What is EVFM's EPS (earnings per share)?
Evofem Biosciences, Inc. (EVFM)'s trailing twelve month EPS is $-0.11 as of 2026-06-30.
What is EVFM's ROE (return on equity)?
Evofem Biosciences, Inc. (EVFM)'s trailing twelve month Return on Equity (ROE) is 19.63% as of 2026-06-30.
What is EVFM's ROA (return on assets)?
Evofem Biosciences, Inc. (EVFM)'s trailing twelve month Return on Assets (ROA) is -140.79% as of 2026-06-30.
What is EVFM's EV/EBITDA?
Evofem Biosciences, Inc. (EVFM)'s trailing twelve month EV/EBITDA is -0.43x as of 2026-06-30.